ArticleTranslational cancer research2025
The identification and prediction of lung adenocarcinoma prognosis using a novel gene signature associated with DNA replication.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comprehensive analysis ofJournal of thoracic disease · 2026Article
- Novel prognostic signature unveils PSEN1 contributes to depression-induced lung adenocarcinoma progression.Frontiers in immunology · 2026Article
- Identification and validation of selenium metabolism-related genes in lung adenocarcinoma prognosis using bioinformatics analysis.Frontiers in genetics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung adenocarcinoma (LUAD) is the most aggressive lung cancer phenotype, and patients' clinical response is often limited by primary or acquired mechanisms of resistance to oncological therapy. One of the current clinical needs is to define clinical predictors for the prognosis of LUAD, aiming at offering patients a persistent treatment likely to delay disease progression as much as possible. This study relies on data from The Cancer Genome Atlas (TCGA) to define the functional roles and prognostic implications of DNA replication-related genes in LUAD. Methods: Clinical features and RNA-sequencing data were collected from 607 LUAD patients from TCGA-LUAD dataset, with the aims to identify the genes related to patient prognosis, and the pathways related to DNA replication in LUAD. Results: A total of 2,412 prognostic genes were obtained, and the DNA replication-related pathways closely associated with LUAD were identified by a Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. TCGA-LUAD patients were divided into a high- (G1) and low- (G2) risk groups based on the 15 DNA replication-related genes (i.e., Conclusions: There is a close relationship between the DNA replication-related genes and the tumor classification of LUAD patients. An innovative signature related to DNA replication was found to be a good prognostic predictor of LUAD. Our findings may provide novel insights into the diagnosis and treatment of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.